Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|August 5, 2023
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysisPauline Corbaux, Benoit You, Rosalind M Glasspool, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET StudyAna Oaknin, Bhavana Pothuri, Lucy Gilbert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid TumorsAlbiruni R Abdul Razak, Morten Mau-Soerensen, Nashat Y Gabrail, et al.
The Lancet. Oncology|July 21, 2018
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trialAmit M Oza, Ursula A Matulonis, Susanne Malander, et al.
Gynecologic Oncology|January 15, 2019
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trialMichel Fabbro, Kathleen N Moore, Anne Dørum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA TrialUrsula A Matulonis, Lydia Walder, Trine J Nøttrup, et al.
Gynecologic Oncology|December 10, 2024
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trialMansoor R Mirza, Line Bjørge, Frederik Marmé, et al.
Gynecologic Oncology|March 26, 2025
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safetyUrsula A Matulonis, Jørn Herrstedt, Amit Oza, et al.
Gynecologic Oncology|January 8, 2016
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 studyPhilipp Harter, Toby Johnson, Dominique Berton-Rigaud, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 18, 2019
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancerDomenica Lorusso, Felix Hilpert, Antonio González Martin, et al.
Pageof 5